News & media

From 1 November 2020, subject to formal approval from the Federal Executive Council, cost recovery arrangements will be extended to cannabis-related manufacture licences and permits under the Medicinal Cannabis Scheme.

The Australian Advisory Council on the Medicinal Use of Cannabis (AACMC), Communiqué #13.

Changes to fees and charges related to the Medicinal Cannabis Scheme under the Narcotic Drugs Act 1967 commenced on 15 July 2020.

Joint media release - Department of Health (ODC) and Australian Border Force.

The Australian Advisory Council on the Medicinal Use of Cannabis (AACMC), Communiqué #12.

The Australian Advisory Council on the Medicinal Use of Cannabis (AACMC), Communiqué #11.

The Australian Advisory Council on the Medicinal Use of Cannabis (AACMC), Communiqué #10.

Submissions in response to the Office of Drug Control's (ODCs) Consultation on Single Licence Model close COB Monday 3 February 2020.

The Office of Drug Control is implementing the 26 recommendations from the Report on the Review of the Narcotic Drugs Act 1967.

Report on the Review into the 2016 medicinal cannabis amendments to the Narcotic Drugs Act 1967 was tabled in Parliament on Thursday 5 September 2019.

The Australian Government will boost the nation's medicinal cannabis industry by prioritising projects that have been granted Major Project Status (MPS) and ultimately driving economic growth.

The Australian Advisory Council on the Medicinal Use of Cannabis (AACMC), Communiqué #9.

The Australian Advisory Council on the Medicinal Use of Cannabis (AACMC), Communiqué #8.

A clarification of the processing rules around the timing of a medicinal cannabis licence and narcotics manufacturing licences.

Professor John McMillan AO appointed to review and report on the operation of the Narcotic Drugs Act 1967.

The TGA will be hosting public meetings in February 2019 in Sydney, Brisbane and Melbourne.

Correcting the record on the 5 December 2016 Australian Financial Review story.

The Australian Advisory Council on the Medicinal Use of Cannabis (AACMC), Communiqué #7.

The Australian Advisory Council on the Medicinal Use of Cannabis (AACMC), Communique #6.

False and misleading claims made by some companies

The Australian Advisory Council on the Medicinal Use of Cannabis (AACMC), Communique #5.

The Australian Advisory Council on the Medicinal Use of Cannabis (AACMC), Communique #4.

Allowing the export of Australian-manufactured medicinal cannabis products.

The Australian Advisory Council on the Medicinal Use of Cannabis (AACMC), Communique #3.

Doctors wishing to prescribe unregistered medicinal cannabis products under SAS Cat A.